BACKGROUND AND OBJECTIVE: Although people of low socioeconomic status (SES) and
certain racial groups are at greater risk of developing diabetic macular edema (DME), the …

Purpose: Although it is clear that minorities and people of low socioeconomic status are at
greater risk of developing Diabetic Macular Edema (DME), it is unclear the extent to which …

BACKGROUND AND OBJECTIVE: This study characterizes the impact of race, ethnicity,
insurance status, and geographic location on anti-vascular endothelial growth factor (VEGF) …

Purpose This study characterizes the association of risk factors including race, ethnicity, and
insurance status with presenting visual acuity (VA) and diabetic retinopathy (DR) severity in …

Purpose Diabetic macular edema (DME), the leading cause of vision loss among patients
with diabetes mellitus, disproportionately affects Black and Hispanic patients. Currently, non …

BACKGROUND AND OBJECTIVE: This study assessed racial and ethnic differences in
receiving anti-vascular endothelial growth factor (VEGF) intravitreal injections among …

BACKGROUND AND OBJECTIVE: To describe the frequency and variation of intravitreal
bevacizumab (Avastin; Genentech, South San Francisco, CA) and ranibizumab (Lucentis; …

Importance While diabetes prevalence among US adults has increased in recent decades,
few studies document trends in diabetes-related eye disease. Objective To examine 10-year …

Purpose To determine the impact of race and ethnicity on efficacy of intravitreal
bevacizumab for diabetic macular edema in anti–vascular endothelial growth factor (VEGF) …

Purpose To assess how patient choices (out-of-pocket costs, insurance plan, geographic
region) impact initiation of therapy for diabetic macular edema (DME). Design Retrospective …